GlassScriptPhysician profile
Carlos A Plata
NPI 1508872029
$19,930.75
in general payments reported to CMS, 2019-2025
44 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,647 · 2020: $2,639 · 2021: $2,893 · 2022: $2,871 · 2023: $3,140 · 2024: $3,578 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,780 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,779.92 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,788.95 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $2,381.99 | 2019-2025 | |
| Ucb, INC. | $2,225.30 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,264.53 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $1,113.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $934.19 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $923.17 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $909.19 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $820.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $808.90 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $728.83 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $620.12 | 2019-2023 | Rituxan, Actemra |
| Lilly USA, LLC | $610.58 | 2019-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $528.81 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $516.15 | 2022-2025 | Purified Cortrophin Gel |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Plata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.